Generic Medicine Info
May be taken with or without food.
Patient w/ myasthenia gravis, severe resp insufficiency including chronic obstructive airways disease w/ incipient resp failure, sleep apnoea syndrome. Severe hepatic impairment.
Special Precautions
Patient w/ CV or cerebrovascular disease, pre-existing or chornic resp disease, acute narrow-angle glaucoma, impaired gag reflex, history of alcohol or drug abuse; at risk of falls. Not intended as primary therapy of depression, anxiety and/or psychosis. Avoid abrupt withdrawal. Renal and mild to moderate hepatic impairment. Elderly, debilitated patients. Pregnancy and lactation. Patient Counselling May impair ability to perform activities requiring mental alertness and motor coordination (e.g. operating machinery, driving). Monitoring Parameters Monitor resp, CV and mental status. Periodic monitoring of CBC and LFTs.
Adverse Reactions
Drowsiness, dizziness, headache, ataxia, decreased alertness, seizures, tremor, incontinence, anterograde amnesia, confusional state, emotional disturbances, libido disorders, muscle weakness and spasm, depression; behavioural, speech and sleep disorders, restlessness, agitation, delusion, irritability, aggressiveness, nightmares, anger, psychoses, hallucinations, diplopia, pruritus and rash, fatigue, cardiac failure, resp depression, anorexia, GI disturbances (e.g. nausea, vomiting).
Drug Interactions
May enhance the activity w/ CYP450 inhibitor (e.g. azole antifungals, macrolides, HIV protease inhibitors, Ca channel blockers). Elevated plasma levels w/ disulfiram or cimetidine. Additive CNS depressant effects w/ barbiturates, sedatives, anaeasth, anxiolytics, hypnotics, phenothiazines, other antipsychotics, skeletal muscle relaxants. May potentiate anticholinergic effects of atropine, antihistamines and antidepressants. Increased psychic drug dependence w/ narcotic analgesics.
CIMS Class
ATC Classification
N05BA08 - bromazepam ; Belongs to the class of benzodiazepine derivatives anxiolytics. Used in the management of anxiety, agitation or tension.
Disclaimer: This information is independently developed by CIMS based on bromazepam from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to CIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, CIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2021 CIMS. All rights reserved. Powered by
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in